For individuals with symptomatic condition necessitating therapy, ibrutinib is often advised according to four phase III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 together with other frequently utilized CIT combinations, namely FCR, bendamustine additionally rituximab and chlorambucil furthermore obinutuzumab